ArticleMolecular medicine reports2019
Identification of exosomal and non‑exosomal microRNAs associated with the drug resistance of ovarian cancer.
Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Exploring miRNA profile associated with cisplatin resistance in ovarian cancer cells.Biochemistry and biophysics reports · 2025Article
- Exosomes: Key Factors in Ovarian Cancer Peritoneal Metastasis and Drug Resistance.Biomolecules · 2024Review
- Unraveling the regulatory cell death pathways in gastric cancer: a multi-omics study.Frontiers in pharmacology · 2024Article
- Functional neuronal circuits promote disease progression in cancer.Science advances · 2023Article
- Liquid biopsy in ovarian cancer in China and the world: current status and future perspectives.Frontiers in oncology · 2023Review
- KAZN as a diagnostic marker in ovarian cancer: a comprehensive analysis based on microarray, mRNA-sequencing, and methylation data.BMC cancer · 2022Article
- Non-Coding RNAs Delivery by Small Extracellular Vesicles and Their Applications in Ovarian Cancer.Frontiers in bioengineering and biotechnology · 2022Review
- Exosomal miR-543 Inhibits the Proliferation of Ovarian Cancer by Targeting IGF2.Journal of immunology research · 2022Article
- Research progress on anti-ovarian cancer mechanism of miRNA regulating tumor microenvironment.Frontiers in immunology · 2022Review
- Current Implications of microRNAs in Genome Stability and Stress Responses of Ovarian Cancer.Cancers · 2021Review
- MicroRNA 617 Targeting SERPINE1 Inhibited the Progression of Oral Squamous Cell Carcinoma.Molecular and cellular biology · 2021Article
- Role of exosomes in the immune microenvironment of ovarian cancer.Oncology letters · 2021Review
- Underlying metastasis mechanism and clinical application of exosomal circular RNA in tumors (Review).International journal of oncology · 2021Review
- Emerging Functions and Clinical Applications of Exosomal ncRNAs in Ovarian Cancer.Frontiers in oncology · 2021Review
- MiR-183-5p induced by saturated fatty acids regulates the myogenic differentiation by directly targeting FHL1 in C2C12 myoblasts.BMB reports · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) serve important roles in drug‑resistance; however, exosomal miRNAs associated with drug‑resistance in ovarian cancer (OC) have not been reported to date. The current study aimed to analyze the drug resistance‑associated exosomal miRNAs in original OC cells and their derived exosomes using microarray data downloaded from the Gene Expression Omnibus database (series GSE76449). The chemosensitive OC cell lines SKOV3_ip1, A2780_PAR and HEYA8, as well as the chemoresistant cell lines SKOV3_TR, A2780_CP20 and HEYA8_MDR, were investigated. Differentially expressed miRNAs (DE‑miRNAs) were identified using the limma method, and their mRNA targets were predicted using the miRWalk and LinkedOmics database. Functions of target genes were analyzed with DAVID tool, while TCGA data were used to explore the survival association of identified miRNAs. According to the results, 28 DE‑miRNAs were found to be common in exosomal and original samples of A2780_CP20 cells, among which the functions of 5 miRNAs were predicted (including miR‑146b‑5p, miR‑509‑5p, miR‑574‑3p, miR‑574‑5p and miR‑760). In addition, 16 and 35 DE‑miRNAs were detected for HEYA8_MDR and SKOV3_TR, respectively, with the functions of 4 of these miRNAs predicted for each cell line (HEYA8_MDR: miR‑30a‑3p, miR‑30a‑5p, miR‑612 and miR‑617; SKOV3_TR: miR‑193a‑5p, miR‑423‑3p, miR‑769‑5p and miR‑922). It was also reported that miR‑183‑5p was the only one common miRNA among the three cell lines. Furthermore, miR‑574‑3p, miR‑30a‑5p and miR‑922 may regulate CUL2 to mediate HIF‑1 cancer signaling pathway, while miR‑183‑5p may modulate MECP2, similar to miR‑760, miR‑30a‑5p and miR‑922, to influence cell proliferation. Finally, the downregulated miR‑612 may promote the expression of TEAD3 via the Hippo signaling pathway, and this miRNA was associated with poor prognosis. In conclusion, the findings of the present study suggested several underlying miRNA targets for improving the chemotherapy sensitivity of OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.